Skip to main content
    P

    PTC Therapeutics Inc (PTCT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $60.36
    -0.61 (-1.00%)

    Market Cap: $5.09B

    Last updated: Nov 17, 2026 at 4:20 PM ET

    PTC Therapeutics Inc (PTCT) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    PTC Therapeutics (PTCT) has a market cap of $5.09B and an enterprise value of $4.63B. Revenue fell 42.84% over the last 12 months from the 12 months before. Its share count is up 6.21% from a year earlier.

    Total Valuation

    Enterprise value is 9.01% below the market cap, as cash exceeds debt.

    Market Cap$5.09B
    Enterprise Value$4.63B
    Latest price (Nov 17, 2026)$60.36

    Key Dates

    The next earnings report is expected on Feb 17, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 17, 2027 (expected)
    Last Earnings DateOct 29, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.59% in the quarter ended Jun 30, 2026 and grew 4.01% a year over 2 years.

    Shares Outstanding83.01M
    Shares Change (YoY)+6.21%
    Shares Change (QoQ)+0.59%
    Share Count Growth (2Y CAGR)+4.01%

    Valuation Ratios

    The price to sales ratio is 5.0x. Its year-end P/S ranged from 2.2x to 10.5x from 2016 to 2025.

    P/S Ratio5.0x
    Forward P/S3.9x

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 29.3x EBITDA.

    EV / Sales4.6x
    EV / EBITDA29.3x
    EV / EBIT39.2x

    Price Statistics

    The stock is down 19.84% over 52 weeks and trades 5.36% below its 50-day average.

    Beta (1Y)0.86
    52-Week Change-19.84%
    1-Month Change-1.90%
    3-Month Change-18.07%
    6-Month Change-14.15%
    5-Year Change+58.11%
    10-Year Change+865.70%
    Total Return (1Y)-19.84%
    Total Return (3Y CAGR)+43.41%
    Total Return (5Y CAGR)+8.90%
    Return vs SPY (1Y)-32.85%
    Max Drawdown (1Y)-33.85%
    Max Drawdown (3Y)-36.70%
    Sharpe Ratio (1Y)-0.56
    Correlation with SPY (1Y)0.28
    50-Day Average$63.78
    200-Day Average$70.02
    52-Week Range$58.80 to $90.87
    RSI (14 Days)41.5
    Average Volume (20 Days)1.07M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 3.39x current liabilities.

    Current Ratio3.39x
    Quick Ratio3.28x
    Debt / EBITDA3.80x

    Returns and Efficiency

    Return on invested capital is 18.05% over the last 12 months, against a 5-year average of 319.83%.

    Return on Assets (ROA)-1.18%
    Return on Invested Capital (ROIC)18.05%
    Return on Capital Employed (ROCE)4.77%
    ROA (5Y Average)-18.12%
    ROIC (5Y Average)319.83%
    Asset Turnover0.34x
    Inventory Turnover0.28x
    Receivables Turnover4.40x
    Cash Conversion Cycle-3991 days

    Scores

    PTCT has an Altman Z-Score of 0.75, in the distress zone below 1.81, and a Piotroski F-Score of 7 of 9, in the average band of 3 to 7.

    Altman Z-Score0.75
    Altman Z ZoneDistress
    Piotroski F-Score7 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $1.01B over the last 12 months.

    Revenue$1.01B
    Revenue Growth (YoY)-42.84%
    Gross Profit$985.09M
    Operating Income$125.60M
    Pretax Income-$67.07M
    Net Income-$38.38M
    EBITDA$155.40M
    EBIT$118.22M
    Reported EPS (TTM)-$0.30

    Trailing 12 months through Jun 30, 2026.

    Full financial statements

    Balance Sheet

    Cash and Equivalents$1.05B
    Total Debt$590.97M
    Net Cash$458.92M
    Net Cash Per Share$5.53
    Working Capital$1.85B
    Shareholder Equity-$165.36M
    Tangible Book Value-$650.63M
    Total Assets$3.25B
    Total Liabilities$3.42B

    Balance sheet as of Jun 30, 2026.

    Full balance sheet

    Cash Flow

    After $9.21M of capital spending, operating cash flow left -$39.71M of free cash flow.

    Operating Cash Flow-$30.50M
    Capital Expenditures$9.21M
    Free Cash Flow-$39.71M
    FCF Per Share-$0.48
    Depreciation and Amortization$73.41M

    Trailing 12 months through Jun 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 12.45%, against a 5-year average of -33.56%.

    Gross Margin97.65%
    Operating Margin12.45%
    Pretax Margin-6.65%
    Net Margin-3.80%
    EBITDA Margin15.41%
    EBIT Margin11.72%
    FCF Margin-3.94%
    Gross Margin (5Y Average)96.10%
    Operating Margin (5Y Average)-33.56%
    Net Margin (5Y Average)-49.93%

    Growth

    Revenue grew 35.30% a year over 3 years.

    Revenue Growth (3Y CAGR)+35.30%
    Revenue Growth (5Y CAGR)+35.37%

    Revenue and profit by year

    Dividends and Yields

    PTCT does not pay a dividend. Its free cash flow yield is -0.79%.

    FCF Yield-0.79%
    Buyback Yield-0.06%
    Shareholder Yield-0.06%

    Peer Position

    Against 8 similar companies, PTCT has the lowest P/S.

    P/S Ratio5.0x vs 12.9x median
    ROIC18.05% vs -23.06% median
    Revenue Growth (Trailing 4 Quarters, YoY)-42.84% vs +37.67% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at -9.13% and EPS growth at -35.21% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)-9.13%
    EPS Growth Forecast (2Y CAGR)-35.21%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About PTCT

    What is PTCT's market cap?

    PTC Therapeutics has a market cap of $5.09B. Its enterprise value, which adds debt and subtracts cash, is $4.63B.

    How many shares of PTCT are outstanding?

    PTC Therapeutics has 83.01M shares outstanding. The count is up 6.21% from a year earlier.

    Does PTCT pay a dividend?

    No. PTC Therapeutics does not pay a dividend.

    How much debt does PTCT have?

    PTC Therapeutics has $590.97M of total debt and $1.05B of cash and equivalents, a net cash position of $458.92M.